SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development

SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development

Cancer immunotherapy (IO) enables patients to live well with cancer for many years, or even be cured. Several investigational IO agents recently failed in early-phase or late-phase trials, leading some to doubt the future of IO. Patient heterogeneity (eg, tumor characteristics, treatment history) in...

Full description

Saved in:
Bibliographic Details
Main Authors: James L Gulley, Leisha A Emens, Patrick Hwu, Carlo B Bifulco, Pamela S Ohashi, Christine Moussion, David Feltquate
Format: Article
Language:English
Published: BMJ Publishing Group 2025-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/6/e010739.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items